UNIV NEW YORK MEDICAL CT has a total of 18 patent applications. Its first patent ever was published in 1994. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are INTERK PEPTIDE THERAPEUTICS LTD, IMMUNE RESPONSE CORP INC and PENN MARC S.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 9 | |
#2 | Australia | 3 | |
#3 | Canada | 2 | |
#4 | EPO (European Patent Office) | 1 | |
#5 | Hong Kong | 1 | |
#6 | Taiwan | 1 | |
#7 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Medical technology | |
#5 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Microorganisms | |
#3 | Therapeutic chemical compounds | |
#4 | Peptides | |
#5 | Analysing materials | |
#6 | Diagnosis and surgery | |
#7 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Bucalo Louis R | 6 |
#2 | Cherksey Bruce | 5 |
#3 | Schneider Robert J | 5 |
#4 | Klein Nicola | 4 |
#5 | Schlessinger Joseph | 3 |
#6 | Le Junming | 2 |
#7 | Ghrayeb John | 2 |
#8 | Daddona Peter | 2 |
#9 | Vilcek Jan | 2 |
#10 | Siegel Scott | 2 |
Publication | Filing date | Title |
---|---|---|
US2007105752A1 | Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma | |
AU2003212985A1 | Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies | |
AU7248100A | Method for gene transfer to the central nervous system | |
CA2274805A1 | Pyk2 related products and methods | |
US6420338B1 | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma | |
US7348178B1 | Recombinant adenoviral vector system | |
US6210664B1 | Method for gene transfer to the central nervous system |